AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27631388 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-based setting using RPE to guide exercise intensity
Number of subjects: 2622
Study 27631388 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based setting using RPE to guide exercise intensity
Number of subjects: 2622
Study 27631388 — intervention group
Group type: COMPARATOR
Intervention: Comparison of center-based and home-based settings
Number of subjects: 2622
Study 25512466 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 500 mg intravenous (ALLO)
Number of subjects: 222
Study 25512466 — intervention group
Group type: COMPARATOR
Intervention: Placebo intravenous (CONT)
Number of subjects: 222
Study 25512466 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (ALLO)
Number of subjects: 222
Study 25512466 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CONT)
Number of subjects: 222
Study 23681034 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA) with propofol
Number of subjects: 33
Study 23681034 — intervention group
Group type: COMPARATOR
Intervention: Inhalational anesthesia (IA) with sevoflurane
Number of subjects: 33
Study 23681034 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA with propofol (subgroup analysis)
Number of subjects: 33
Study 23681034 — intervention group
Group type: COMPARATOR
Intervention: IA with sevoflurane (subgroup analysis)
Number of subjects: 33
Study 23681034 — intervention group
Group type: COMPARATOR
Intervention: IA with sevoflurane
Number of subjects: 33
Study 23681034 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA with propofol
Number of subjects: 33
Study 20802165 — intervention group
Group type: EXPERIMENTAL
Intervention: Written action plan coupled with a prescription (WAP-P)
Number of subjects: 219
Study 20802165 — intervention group
Group type: COMPARATOR
Intervention: Unformatted prescription (UP)
Number of subjects: 219
Study 19166993 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful self-focus induction
Number of subjects: 76
Study 19166993 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction induction
Number of subjects: 76
Study 19166993 — intervention group
Group type: COMPARATOR
Intervention: Rumination induction
Number of subjects: 76
Study 19166993 — intervention group
Group type: COMPARATOR
Intervention: Habitual distraction
Number of subjects: 76
Study 19166993 — intervention group
Group type: COMPARATOR
Intervention: Habitual mindfulness
Number of subjects: 76
Study 17664863 — intervention group
Group type: EXPERIMENTAL
Intervention: Conivaptan 40 mg/day
Number of subjects: 84
Study 17664863 — intervention group
Group type: EXPERIMENTAL
Intervention: Conivaptan 80 mg/day
Number of subjects: 84
Study 17664863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 16105056 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet (30 to 180 mg once daily)
Number of subjects: 410
Study 16105056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study 16105056 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 410
Study 12200100 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced dissemination strategy (video, personalized child development information, supportive telephone calls)
Number of subjects: 498
Study 12200100 — intervention group
Group type: COMPARATOR
Intervention: Standard dissemination strategy (control group)
Number of subjects: 498
Study 12200100 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced dissemination strategy
Number of subjects: 498
Study 10199774 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at a mean dose of 1 UI/day for 1 year
Number of subjects: 33
Study 10199774 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at a mean dose of 1 UI/day for 2 years
Number of subjects: 33
Study 10199774 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 33
Study 8568547 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin 150 or 300 mg administered intramuscularly (i.m.)
Number of subjects: 12
Study 8568547 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin 300 mg administered intramuscularly (i.m.)
Number of subjects: 12
Study 2269380 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical MC 903 ointment (50 micrograms/g) alone
Number of subjects: 20
Study 2269380 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of topical MC 903 with UVB radiation
Number of subjects: 20
Study 2269380 — intervention group
Group type: COMPARATOR
Intervention: Control (Topical MC 903 alone)
Number of subjects: 20
Study 2269380 — intervention group
Group type: COMPARATOR
Intervention: Control (Combination with UVB)
Number of subjects: 20
Study 6457309 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 40
Study 6457309 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 40
Study 6457309 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 31487718 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV NAVA
Number of subjects: 40
Study 31487718 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 40
Study 28916664 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous carotid endarterectomy + CABG
Number of subjects: 129
Study 28916664 — intervention group
Group type: COMPARATOR
Intervention: Isolated CABG
Number of subjects: 129
Study 25845918 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 80
Study 25845918 — intervention group
Group type: COMPARATOR
Intervention: FDA ≥30% criterion
Number of subjects: 80
Study 25845918 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistically reliable changes on the VAS for 68% and 95% confidence intervals
Number of subjects: 80
Study 23700406 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin administration over an 8-week period
Number of subjects: 0
Study 23700406 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin and its analogs ([Ser4, Ile8]-oxytocin, [Asu1,6]-oxytocin) in mouse models
Number of subjects: 0
Study 23700406 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin or its analogs in streptozotocin-induced diabetic mouse model
Number of subjects: 0
Study 20530042 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week supervised exercise intervention
Number of subjects: 21
Study 20530042 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week supervised exercise intervention followed by 12 weeks of self-administered exercise
Number of subjects: 21
Study 20530042 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 19246445 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (21 mg)
Number of subjects: 209
Study 19246445 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 209
Study 19246445 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence
Number of subjects: 209
Study 19246445 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 209
Study 16997602 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of a single 2 ml dose of hylan G-F 20 into the hip joint under fluoroscopic guidance.
Number of subjects: 56
Study 15598477 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 8 mg/d
Number of subjects: 300
Study 15598477 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 16 mg/d
Number of subjects: 300
Study 15598477 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/d
Number of subjects: 300
Study 15598477 — intervention group
Group type: COMPARATOR
Intervention: Community control (untreated)
Number of subjects: 300
Study 15598477 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (all doses combined)
Number of subjects: 300
Study 11903737 — intervention group
Group type: COMPARATOR
Intervention: L-regimen (30 mg lansoprazole u.i.d)
Number of subjects: 42
Study 11903737 — intervention group
Group type: EXPERIMENTAL
Intervention: LC-regimen (30 mg lansoprazole u.i.d. with 200 mg cetraxate q.i.d)
Number of subjects: 42
Study 11903737 — intervention group
Group type: COMPARATOR
Intervention: Control group (H. pylori-negative patients)
Number of subjects: 42
Study 9215029 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous extradural infusion of ropivacaine 2 mg ml-1 at 4 ml h-1
Number of subjects: 133
Study 9215029 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous extradural infusion of ropivacaine 2 mg ml-1 at 6 ml h-1
Number of subjects: 133
Study 9215029 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous extradural infusion of ropivacaine 2 mg ml-1 at 8 ml h-1
Number of subjects: 133
Study 9215029 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous extradural infusion of ropivacaine 2 mg ml-1 at 10 ml h-1
Number of subjects: 133
Study 9215029 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 133
Study 8356864 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg.kg‐1 propofol
Number of subjects: 20
Study 8356864 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution (Control)
Number of subjects: 20
Study 3301981 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-polymerized fissure sealant
Number of subjects: 0
Study 3301981 — intervention group
Group type: COMPARATOR
Intervention: Autopolymerized fissure sealant
Number of subjects: 0
Study 29067578 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal low rectal dissection
Number of subjects: 100
Study 29067578 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic low rectal dissection
Number of subjects: 100
Study 27532874 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly telephone intervention for three months
Number of subjects: 140
Study 27532874 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 140
Study 24972492 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 207
Study 24972492 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation intervention
Number of subjects: 207
Study 24972492 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 207
Study 22838094 — intervention group
Group type: EXPERIMENTAL
Intervention: OTC BPO 5.5% formulation with lipohydroxy acid and tretinoin cream 0.025%
Number of subjects: 0
Study 22838094 — intervention group
Group type: COMPARATOR
Intervention: Prescription clindamycin 1%-BPO 5% gel and tretinoin cream 0.025%
Number of subjects: 0
Study 20542783 — intervention group
Group type: EXPERIMENTAL
Intervention: Early FFR-guided PCI (invasive group)
Number of subjects: 121
Study 20542783 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (conservative group)
Number of subjects: 121
Study 18052855 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief behavioral cessation intervention
Number of subjects: 50
Study 18052855 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive behavioral cessation intervention
Number of subjects: 50
Study 18052855 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 50
Study 16225497 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg intravenous)
Number of subjects: 28
Study 16225497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 12373416 — intervention group
Group type: EXPERIMENTAL
Intervention: Flesinoxan 0.5 mg
Number of subjects: 12
Study 12373416 — intervention group
Group type: EXPERIMENTAL
Intervention: Flesinoxan 1 mg
Number of subjects: 12
Study 12373416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10404500 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose of ethanol (0.5 g.kg‐1)
Number of subjects: 11
Study 10404500 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-free drink (control)
Number of subjects: 11
Study 8524562 — intervention group
Group type: EXPERIMENTAL
Intervention: Community care by glaucoma-trained optometrists with reviews on a six monthly basis
Number of subjects: 405
Study 8524562 — intervention group
Group type: COMPARATOR
Intervention: Routine Hospital Eye Services (HES) monitoring
Number of subjects: 405
Study 2178961 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 1.6 mg
Number of subjects: 18
Study 2178961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 6108129 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (HC 20-511) 1 mg twice daily for 12 weeks
Number of subjects: 35
Study 6108129 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate (SCG) 20 mg four times daily for 12 weeks
Number of subjects: 35
Study 6108129 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (HC 20-511)
Number of subjects: 35
Study 6108129 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 35
Study 31911007 — intervention group
Group type: EXPERIMENTAL
Intervention: SGO Wellness Curriculum
Number of subjects: 73
Study 29738417 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (VitD) supplementation 1000 IU VitD3/day for 9 months
Number of subjects: 160
Study 29738417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 26741799 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual n-back working memory task
Number of subjects: 0
Study 26741799 — intervention group
Group type: COMPARATOR
Intervention: Demanding visuospatial attention task
Number of subjects: 0
Study 23794382 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 10 mg IV
Number of subjects: 41
Study 23794382 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 41
Study 23163117 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day)
Number of subjects: 77
Study 23163117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 20517223 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin, 425 mg, 2 tablets twice a day during 25 days
Number of subjects: 60
Study 20517223 — intervention group
Group type: COMPARATOR
Intervention: Aminalon, 500 mg, 2 tablets 3 times a day during 25 days
Number of subjects: 60
Study 18930718 — intervention group
Group type: EXPERIMENTAL
Intervention: Active following (Go-Go trials)
Number of subjects: 0
Study 18930718 — intervention group
Group type: COMPARATOR
Intervention: Passive observation (NoGo-Go trials)
Number of subjects: 0
Study 18930718 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized trials (Rnd)
Number of subjects: 0
Study 15907400 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 60
Study 15907400 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 6 mg
Number of subjects: 60
Study 12620596 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified duty
Number of subjects: 165
Study 12620596 — intervention group
Group type: COMPARATOR
Intervention: Not working
Number of subjects: 165
Study 10817549 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg of rofecoxib once daily
Number of subjects: 784
Study 10817549 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of rofecoxib once daily
Number of subjects: 784
Study 10817549 — intervention group
Group type: COMPARATOR
Intervention: 50 mg of diclofenac 3 times daily
Number of subjects: 784
Study 8803643 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (C 50 mg bid)
Number of subjects: 24
Study 8803643 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (T 250 mg bid)
Number of subjects: 24
Study 8803643 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril plus Ticlopidine (C plus T)
Number of subjects: 24
Study 8803643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8803643 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril plus Ticlopidine (C plus T) for twelve months
Number of subjects: 24
Study 1465278 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C + high-dose medroxyprogesterone acetate (MMPA)
Number of subjects: 34
Study 1465278 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide + doxorubicin + fluorouracil (CAF)
Number of subjects: 34
Study 6701301 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 46
Study 6701301 — intervention group
Group type: COMPARATOR
Intervention: metrizamide
Number of subjects: 46
Study 30756462 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 0
Study 30756462 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 0
Study 30756462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30589889 — intervention group
Group type: EXPERIMENTAL
Intervention: Anomalous word neighbours of plausible words
Number of subjects: 30
Study 30589889 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrelated anomalous words
Number of subjects: 30
Study 30589889 — intervention group
Group type: EXPERIMENTAL
Intervention: Anomalous word neighbour condition
Number of subjects: 30
Study 30589889 — intervention group
Group type: COMPARATOR
Intervention: Plausible condition
Number of subjects: 30
Study 30589889 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent component analysis (ICA)
Number of subjects: 30
Study 26833461 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal administration of 125‐mg, 250‐mg, or 500‐mg AZM suppository
Number of subjects: 5
Study 26833461 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of AZM 500‐mg tablet
Number of subjects: 5
Study 25785316 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg bolus before intubation, followed by 2 mg/kg/h continuous infusion)
Number of subjects: 55
Study 25785316 — intervention group
Group type: COMPARATOR
Intervention: Saline (same dosage as lidocaine)
Number of subjects: 55
Study 22233205 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginsenoside‐Rd
Number of subjects: 390
Study 22233205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study 20381159 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 87
Study 20381159 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine
Number of subjects: 87
Study 18377121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 150
Study 18377121 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Therapy only (CPT-C)
Number of subjects: 150
Study 18377121 — intervention group
Group type: COMPARATOR
Intervention: Written Accounts (WA)
Number of subjects: 150
Study 15488899 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective hippocampal damage
Number of subjects: 0
Study 15488899 — intervention group
Group type: EXPERIMENTAL
Intervention: MTL damage including perirhinal cortex
Number of subjects: 0
Study 12740799 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling group (2/3 of patients)
Number of subjects: 38876
Study 12740799 — intervention group
Group type: COMPARATOR
Intervention: Cross-validation group (1/3 of patients)
Number of subjects: 38876
Study 10333154 — intervention group
Group type: EXPERIMENTAL
Intervention: ePTFE membrane implantation
Number of subjects: 33
Study 10333154 — intervention group
Group type: COMPARATOR
Intervention: No material implanted (control group)
Number of subjects: 33
Study 8706484 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B in lipid emulsion (20% intralipid)
Number of subjects: 60
Study 8706484 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B in 5% dextrose in water
Number of subjects: 60
Study 1908314 — intervention group
Group type: EXPERIMENTAL
Intervention: buserelin/hMG
Number of subjects: 373
Study 1908314 — intervention group
Group type: COMPARATOR
Intervention: CC/hMG
Number of subjects: 373
Study 6478567 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise training (n = 66)
Number of subjects: 198
Study 6478567 — intervention group
Group type: EXPERIMENTAL
Intervention: Group exercise training (n = 61)
Number of subjects: 198
Study 6478567 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill testing at 3 weeks without subsequent training (n = 34)
Number of subjects: 198
Study 6478567 — intervention group
Group type: COMPARATOR
Intervention: Control group (treadmill testing for the first time at 26 weeks, n = 37)
Number of subjects: 198
Study 30265171 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane stem cell‐conditioned medium (AMSC‐CM)
Number of subjects: 48
Study 30265171 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 48
Study 30168415 — intervention group
Group type: EXPERIMENTAL
Intervention: Namilumab 80 mg
Number of subjects: 32
Study 30168415 — intervention group
Group type: EXPERIMENTAL
Intervention: Namilumab 150 mg
Number of subjects: 32
Study 30168415 — intervention group
Group type: EXPERIMENTAL
Intervention: Namilumab 300 mg
Number of subjects: 32
Study 30168415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 26742607 — intervention group
Group type: EXPERIMENTAL
Intervention: ProBalance Programme (n=27)
Number of subjects: 52
Study 26742607 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (n=25)
Number of subjects: 52
Study 24930436 — intervention group
Group type: EXPERIMENTAL
Intervention: adapalene in combination with a moisturizer (heparinoid)
Number of subjects: 100
Study 24930436 — intervention group
Group type: COMPARATOR
Intervention: adapalene alone
Number of subjects: 100
Study 19473997 — intervention group
Group type: COMPARATOR
Intervention: HSV suppressive treatment (placebo-controlled)
Number of subjects: 1305
Study 19473997 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent sex
Number of subjects: 1305
Study 19473997 — intervention group
Group type: EXPERIMENTAL
Intervention: Using cloths or cotton wool for menstrual hygiene
Number of subjects: 1305
Study 19473997 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV
Number of subjects: 1305
Study 19473997 — intervention group
Group type: EXPERIMENTAL
Intervention: Inserting substances to dry the vagina for sex
Number of subjects: 1305
Study 15051595 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss
Number of subjects: 316
Study 15051595 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 316
Study 15051595 — intervention group
Group type: COMPARATOR
Intervention: Healthy lifestyle control
Number of subjects: 316